Gene Editing for Cancer: How CRISPR Is Changing Treatment

How Gene Editing Is Being Used Against Cancer

Cancer is not a single disease — it's hundreds of diseases, each with different genetic drivers. That's what makes gene editing such a promising tool: it can be tailored to target the specific genetic changes that fuel each type of cancer.

Researchers are using gene editing in several ways to fight cancer, from making immune cells more effective to directly targeting tumor cells. While most approaches are still in clinical trials, the results so far have been encouraging.

Key Approaches

CRISPR and CAR-T Therapy: A Deeper Look

CAR-T (Chimeric Antigen Receptor T-cell) therapy is already one of the most exciting developments in cancer treatment. Adding CRISPR gene editing makes it even more powerful.

Here's how the process works:

1. Collect: T cells (a type of immune cell) are collected from the patient or a donor
2. Edit: CRISPR is used to make precise changes — adding a receptor that targets cancer cells, removing genes that tumors use to evade the immune system, or both
3. Expand: The edited cells are grown into large numbers in the lab
4. Infuse: The enhanced cells are infused back into the patient to seek and destroy cancer

Cancer Types Being Studied

Gene editing approaches are being researched across many cancer types:

• Blood cancers — Leukemia, lymphoma, and myeloma have the most advanced CRISPR clinical trials
• Lung cancer — CRISPR-edited immune cells being tested in non-small cell lung cancer
• Liver cancer — Direct in-vivo gene editing approaches being explored
• Brain tumors — Glioblastoma targeted with engineered immune cells
• Pancreatic cancer — Early-stage research combining gene editing with immunotherapy
• Sarcomas — Rare connective tissue cancers targeted with gene-edited cell therapies
• Solid tumors — Broad research programs targeting multiple solid tumor types

Clinical Trials for Cancer Gene Editing

As of 2026, there are over 874 active clinical trials involving gene editing for cancer. Most are in Phase I or Phase II, focused on establishing safety and early efficacy. Key areas include:

• CRISPR-edited autologous CAR-T cells (using the patient's own cells)
• CRISPR-edited allogeneic CAR-T cells (using donor cells)
• T-cell receptor (TCR) therapies enhanced with gene editing
• In-vivo tumor gene editing (delivering CRISPR directly to tumors)
• Gene-edited natural killer (NK) cells

Learn more about how clinical trials work and how to find trials: Clinical Trials for Gene Therapy

Results So Far

Early results from CRISPR cancer trials have been promising:

• The first CRISPR cancer trial (2020) demonstrated that CRISPR-edited T cells could be safely administered and persist in patients for months
• Multiple trials have shown that removing the PD-1 gene from T cells (a gene tumors exploit to hide) improves anti-tumor activity
• Allogeneic (donor-derived) CRISPR-edited CAR-T cells have shown responses in patients who failed previous treatments
• The combination of multiple gene edits in a single cell therapy is proving feasible and potentially more effective

Current Challenges

Despite the promise, significant challenges remain:

• Solid tumors: Most success has been in blood cancers. Solid tumors are harder to penetrate and have more complex immune-evasion strategies
• Durability: How long edited cells remain effective is still being studied
• Manufacturing: Creating personalized gene-edited cell therapies is complex and expensive
• Off-target effects: Ensuring edits only happen where intended remains a priority
• Cost: Current cell therapies can cost hundreds of thousands of dollars per patient

The Future of Gene Editing in Cancer

The field is moving rapidly. Here's what's expected in the coming years:

• Off-the-shelf CRISPR cell therapies that don't require using the patient's own cells
• Multi-edit approaches that make immune cells resistant to multiple tumor defense mechanisms simultaneously
• In-vivo gene editing that targets tumors directly without removing any cells
• Lower costs as manufacturing scales and universal donor cells become available
• Combination strategies pairing gene editing with checkpoint inhibitors, radiation, and other therapies